Vitro S.A. (VitroGroup) of Sevilla at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option

Vitro S.A. (VitroGroup)

Calle Luis Fuentes Bejarano 60 Edif. Nudo Norte Local 3, 21020 Sevilla
Telephone +34 91 3821620
Fax +34 91 7636668

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

Hall map

MEDICA 2021 hall map (Hall 3): stand E34

Fairground map

MEDICA 2021 fairground map: Hall 3


Marta Varela

Marketing assitant



Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our range of products

Product categories

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.01  Immuno assay testing

Immuno assay testing

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.03  Diagnostic tests for cancer

Diagnostic tests for cancer

  • 03  Diagnostic tests
  • 03.02  Immunochemistry testing, immunology testing
  • 03.02.04  Other equipment for immunochemistry and immunology

Other equipment for immunochemistry and immunology

  • 03  Diagnostic tests
  • 03.04  Microbiology testing
  • 03.04.01  Bacteriology testing in microbiology

Bacteriology testing in microbiology

  • 03  Diagnostic tests
  • 03.04  Microbiology testing
  • 03.04.04  Other microbiology testing

Other microbiology testing

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.01  Bacteriology testing

Bacteriology testing

  • 03  Diagnostic tests
  • 03.05  Infectious immunology testing
  • 03.05.02  Microbiological diagnosis, virology, equipment and systems for

Microbiological diagnosis, virology, equipment and systems for

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.01  DNA testing

DNA testing

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.02  Molecular biomarkers

Molecular biomarkers

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.03  Polymerase chain reaction (PCR)

Polymerase chain reaction (PCR)

  • 03  Diagnostic tests
  • 03.06  Genetic testing, molecular diagnostics
  • 03.06.04  Other molecular diagnostics testing

Other molecular diagnostics testing

  • 06  IT systems and IT solutions
  • 06.05  Administrative information systems / software
  • 06.05.01  Healthcare information systems / software (HIS)

Healthcare information systems / software (HIS)

  • 06  IT systems and IT solutions
  • 06.05  Administrative information systems / software
  • 06.05.08  Other administrative information systems / software

Other administrative information systems / software

  • 06  IT systems and IT solutions
  • 06.06  Medical information systems / software
  • 06.06.03  Intranet software

Intranet software

  • 06  IT systems and IT solutions
  • 06.06  Medical information systems / software
  • 06.06.06  Other medical information systems / software

Other medical information systems / software

Company news



16 Feb 2021

Vitro S.A. launches a first-in-class SARS-CoV-2 antibody test with unprecedented performance, to be used as a confirmatory test for the vaccinated population

  • The Jurkat S-flow cytometry test features the use of the complete S protein displayed in its native conformation on the cell membrane of Jurkat cells.
  • Results are collected by flow cytometry, an advanced technology with superior performance and an ultra-wide dynamic range.
  • The test affords unmatched specificity and sensitivity (99% agreement with neutralization assays).
  • The test is especially suited as a confirmatory test for the vaccinated population, although it can also be used to interrogate the presence of antibodies after natural infection.
  • Only a few drops of blood are needed which can be collected with a painless finger prick.
  • The test will be available as soon as February 15th and will be compatible with self-collected capillary blood through an accompanying self-collection kit.
Madrid. February 16th, 2021.
Vitro S.A., the Spanish corporate group developing, manufacturing, and distributing devices, software, and reagents for in-vitro diagnostics (IVD) is releasing a new diagnostic test for the detection of antibodies against SARS-CoV-2, the virus that causes Covid-19, with unprecedented analytical and clinical performance: the Jurkat S-flow cytometry test.

This novel antibody detection test has been developed by the research team led by Dr. Balbino Alarcón at CSIC (Consejo Superior de Investigaciones Científicas). It only needs a few drops of blood and achieves a 99% sensitivity as compared with neutralization assays.

Jurkat cells, which are grown in suspension and are optimal for flow cytometry studies, were engineered to produce and expose the SARS-CoV-2 Spike protein (S protein) on their cell membrane. The viral S protein, which was confirmed to be in its native trimeric form and to induce syncytia formation, is produced in the cells in parallel to a control protein that is also exposed on the surface of Jurkat cells. After incubating the patient’s serum with a cocktail of fluorescent antibodies against the control protein and anti-S immunoglobulins, , the cells are acquired in the flow cytometer and the resulting data is processed using the control protein for data correction and normalization.

As detailed in the ahead-of-print on-line publication in EMBO Molecular Medicine (Horndler L et al, published on-line on January 20th: , Dr. Alarcón’s team performed a thorough validation of this technology, comparing it to several other serological tests. For this purpose, Dr. Alarcón’s team used different sample sets (more than 600 samples overall) comprising serum samples covering the entire clinical spectrum (from asymptomatic to severe disease), and sera collected from donors before the Covid-19 pandemic as negative controls. The Jurkat S-flow cytometry test showed an exquisite specificity in sera from pre-Covid-19 donors (100%) proving to be the one test able to detect the highest number of positives, and calling clear positives where other methods fail to yield a concise result (i.e. results within the “gray area”). It also showed a nearly perfect correlation with neutralization assays (99%), which evaluate the capacity of the tested sera to decrease or prevent the infection of ACE2-expressing cultured cells when confronted with lentiviral particles coated with the SARS-CoV-2 S protein (i.e. pseudotyped virus). In addition, the Jurkat S-flow cytometry test proved to be compatible with serum from capillary blood.

The test will be offered by Vitro S.A. as a reliable option for those who wish or need to confirm that they have developed antibodies against the virus after vaccination, which could be key for a safe return to their routines. Also, it will help decide vaccination priority.

Vitro S.A. will also release and accompanying self-collection kit that will be available at the network of medical centers managed by Vitro S.A.’s partner Recovid Solutions. Capillary blood self-sampling facilitates testing -- helping increase testing rate -- and contributes to reducing the risk of disease transmission by avoiding the need of venopuncture, therefore preventing the exposure of healthcare workers. Once dropped off at the medical centers the samples will be sent to Vitro S.A. laboratories in Granada where the Jurkat S-flow cytometry test is conducted by trained laboratory staff with state-of-the-art technology and in compliance with the highest quality standards.

In Javier Fernandez’s (Vitro S.A.’s CEO) words: “our company is once again at disposal of science and innovation in the restless fight against Covid-19. This novel test will prove to be key to decide priority of vaccination and to allow an effective monitoring of vaccination results, which will get us closer to the end of the pandemic”.

Collaborating in the fight against the pandemic

This new test reaffirms Vitro’s continued commitment to the fight against the coronavirus pandemic. As part these efforts Vitro launched the IVD test “Respiratory Flow Chip” this past July. The test simultaneously detects 21 respiratory pathogens: three species of bacteria and 18 virus species including SARS-CoV-2 and.

Also, Vitro recently validated clinically its RNA extraction kit and its RT-qPCR SARS-CoV-2 test, which together with the traceability software OpenVTR -- also developed by Vitro -- enable the use of Opentrons robots, many of which are available at the largest hospitals in Spain.

In addition, Vitro has also released a IVD kit for detecting Influenza A (FluA), Influenza B (FluB) and SARS-CoV-2 in a single Real Time RT-qPCR Multiplex One-step reaction.

More Less

01 Oct 2020

Vitro releases a PCR platform that multiplies the current diagnostic capacity of COVID-19

  • The combination of a new RNA extraction test, a SARS-CoV-2 RT-PCR test and a traceability software for the OT-2 Opentrons robots already available in over 15 large Spanish hospitals, will allow hospitals to optimize their use and multiply the current capacity to perform daily PCRs with their OT-2 robots in a fully automated way.
  • Vitro S.A. becomes the official distributor of Opentrons in Spain, and validates its reagents and software in the Opentrons robots located at the Virgen del Rocío University Hospital (Seville).
  • All Vitro’s reagents are produced in Spain. Additionally, Vitro is licensee of the extraction technology developed by the Carlos III Health Institute for the Opentrons platforms, and thus eliminating the dependence on the supply of tests and reagents manufactured outside Spain.
  • Besides, the new RT-PCR FluCovid test by Vitro released in August allows hospitals to differentiate patients infected with influenza from those infected with SARS-CoV-2 in a single test.
Madrid, October 01, 2020.
Vitro S.A., the corporate group based in Seville and specialized in the development, manufacture and distribution of instruments, software and reagents for In Vitro Diagnostics (IVD), has just clinically validated its RNA extraction test -first step in the analysis of gene expression- and its RT-PCR-SARS-CoV-2 test so that, along with its own traceability software OpenVTS -designed to speed up and optimize processes- they can be used on the Opentrons robots already available in over 15 large Spanish hospitals achieving to multiply the current diagnostic capacity, which is key during these moments when new COVID-19 outbreaks are occurring.

Up to now, there was a lack of a comprehensive solution that prevented the optimization of the Opentrons robots for the diagnosis of COVID-19 in most hospitals: the lack of a technology capable of providing reagents, traceability software, optimized working protocols and the capacity to integrate these robots into the IT systems. These constraints have been finally solved by Vitro, whose reagents, protocol and software adapted to Opentrons allow performing hundreds of PCRs on a daily basis with just two OT-2 robots, multiplying the current capacity and allowing hospitals to scale their diagnostic capacity with the simultaneous use of 2 to 10 robots.

Vitro, with over 30 years of experience in the supply of reagents and diagnostic platforms to Spanish hospitals, has made major breakthroughs during the months in which the COVID-19 virus advanced in Spain. Therefore, it released a new RT-PCR test for SARS-CoV-2 in April, validated by the Carlos III Health Institute with 100% sensitivity and specificity, and in July it became the first company in the field of hospital diagnosis to commercialize a multiplex test capable of analyzing 23 virus causing respiratory diseases simultaneously, including the diagnosis of COVID-19. Lastly, in August it released its second RT-PCR Flu-Covid kit to the market, becoming the first company in the field to create a CE IVD kit capable of diagnosing Influenza A, Influenza B and SARS-CoV-2 (COVID-19) with the same test, allowing a differential diagnosis of these viruses in a key moment right before the beginning of the influenza season.

The CEO of Vitro, Javier Fernández, stated: “Vitro is one of the diagnostic test manufacturers in Spain that is strongly aiding the hospitals of our country in the diagnosis of COVID-19. We have already developed three different diagnostic tests for this virus in the last five months, proving our technological capacity to solve complex diagnostic needs in a short period of time. The development of a set of three tests, protocols and software by our company to implement them in the super-robots Opentrons, unique for their simplicity, sturdiness and low cost, allows multiplying the current capacity of processing PCRs at the hospitals where the Opentrons robots are used. This major improvement, along with the capacity of diagnosing infections with influenzaviruses and Covid simultaneously, the arrival of autumn and facing this second wave of infections, substantially strengthens the diagnostic capacity of our hospitals and diagnostic labs”.

Cost reduction and logistic enhancements
The experience of Vitro in molecular biology has allowed it to become the first licensee in the RNA extraction technology developed by the Carlos III Health Institute in Opentrons robots for the diagnosis of COVID-19. This new extraction technology, validated in thousands of clinical specimens, allows the hospitals to perform thousands of PCRs on a daily basis in an automated way using the OT-2 Opentrons robots. This capacity represents an enormous advantage in terms of cost reduction, and in addition, the national production of Vitro of this type of reagents is decisive in allowing the large hospitals in Spain to have a national supply source, avoiding the logistic problems of importing tests and reagents manufactured outside Spain.

In addition, the North American company Opentrons has signed a distribution contract with Vitro for its OT-2 robots for the Spanish market, thus recognizing the capacity of the Andalusian company to develop innovative hospital diagnostic platforms. Jon Martinez, director of sales at Opentrons, asserts: “Vitro has proven to be a very capable technological partner to help Spanish institutions and organizations to configure and optimize the use of our robots. We are very excited to continue working with Vitro to increase and improve the use of the Opentrons robotic platforms by new users in Spain who need the assistance and help of a local technological and industrial partner”.

The Virgen del Rocío University Hospital (Seville) has been the first hospital to benefit from an immediate and significant increase in its COVID-19 diagnostic capacity through the use of the "super-robots” Opentrons combined with Vitro’s PCR technology and reagents. The pharmacist specializing in Microbiology and Clinical Biochemistry, Pedro Camacho Martínez, as head of the section, has made an enormous effort, dedicating many hours of work in collaborating with Vitro to fine-tune its Opentrons robots, which has allowed the Microbiology Service to manage a significant increase in the number of PCRs processed each day: "The installation of Vitro technology and reagents in our Opentrons robots has allowed our hospital to considerably increase its capacity, which is essential in view of the increase in the number of PCRs to be performed every day for the diagnosis of COVID-19".

Vitro is in the phase of implementing this important technological improvement in a large part of the rest of the Opentrons-user hospitals, and is awaiting the possible award by INGESA of the supply of Opentrons robots and Covid technology, protocols and diagnostic reagents developed by Vitro and the Carlos III Health Institute to the rest of the Spanish healthcare sector.

The impact of Vitro's technology, reagents, protocol and software in a hospital that has, for example, 8 Opentrons robots, working 24 hours a day, would allow its diagnostic laboratory to perform up to 4500 PCRs daily with minimal staff intervention. Thus, hospitals have great flexibility to increase or decrease this capacity, increasing or reducing the Opentrons OT-2 robots used simultaneously as needed.


More Less

14 Jul 2020

Vitro releases a new in vitro diagnostic test for the simultaneous detection of the virus of the COVID-19 and other 20 respiratory pathogens

  • The multiplex test “Respiratory Flow Chip” allows diagnostic laboratories to identify the virus or bacterium causing the respiratory infection from a single sample.
  • Vitro S.A. is the first company worldwide to commercialize a test covering such a large respiratory viral panel, including SARS-CoV-2.
Madrid, July 14, 2020.
Vitro S.A., the Spanish corporate group specialized in the development, manufacture and distribution of In Vitro Diagnostic (IVD) instruments, software and reagents, has released a new In Vitro Diagnostic test, named “Respiratory Flow Chip” to detect 21 respiratory pathogens simultaneously, including 18 viral species, SARS-CoV 2 and three bacterial species. This way, it becomes the first company worldwide to commercialize a test covering such a large respiratory viral panel.

This new IVD kit for the identification of the nucleic acids of SARS-CoV-2 and other 20 pathogens causing the main acute respiratory infections is highly sensitive and specific. It has a very high value, since it allows identifying, in a single laboratory test, the virus causing the respiratory infection, and thus shortening diagnostic times and simplifying decision-making in terms of isolation of the patient depending on the type of virus causing the infection.

The test commercialized by Vitro is performed on samples of nasopharyngeal smear or bronchoalveolar lavages from people suspected of COVID-19. Once the sample has been collected by healthcare workers with the “Respiratory Flow Chip” kit, it is processed in the diagnostic laboratories in a quick and fully automated way. This test includes all the necessary reagents to treat the sample, including the capture chip where the genome sequences specific to the 21 pathogens under study are located. Besides detecting the SARS-CoV-2, the new test also identifies the Influenza A virus. Influenza B virus, Respiratory Syncytial Virus, Rhinovirus, Enterovirus, Human Parainfluenza Virus, Adenovirus, Metapneumovirus and the bacteria Bordetella pertussis and parapertussis and Mycoplasma pneumoniae.

The “Respiratory Flow Chip” test is processed automatically by the robotized instruments hybriSpotTM, which combine the PCR technique and the reverse flow-through technology. This way, the new Vitro’s product allows analyzing up to 24 samples from patients simultaneously, issuing the result report in less than 3 hours.

The hybriSpotTM platforms offer a versatile, effective and economic solution for the simultaneous diagnosis of the genetic material from these respiratory pathogens and other panels of multiple pathogens causing diverse diseases. Moreover, these robots are enhanced and manufactured by Vitro at its facilities in Seville, where the management and analysis software for all the tests that make up its hybriSpotTM product portfolio are also developed. Vitro designs and produces all the tests and reagents by itself at its facilities in Granada. These diagnostic platforms have the CE-IVD marking and are currently commercialized both in Spain and in over 30 countries.

The “Respiratory Flow Chip” test is the third diagnostic test commercialized by Vitro in Spain aimed at fighting COVID-19. The corporate group in Seville has developed and commercializes a RT-CPR test to detect the nucleic acid of SARS-CoV-2, which was validated by the Carlos III Health Institute with 100% sensitivity and specificity. Additionally, and according to the distribution activity Vitro does selectively for some foreign manufacturers of IVD platforms and tests, the company distributes exclusively in Spain the serology-based test for the detection of IgM and IgG antibodies in blood against SARS-CoV-2 produced by the manufacturer Snibe (China). It has recently introduced in Spain the first certified kit for the detection of SARS-CoV-2 neutralizing antibodies, produced by the manufacturer Genscript and thus strengthening its portfolio of serology-based tests.

During the first three months of the health crisis, the IgM and IgG tests against the COVID-19 supplied by Vitro and manufactured by Snibe have covered 40% of the health needs in Spain. In this regard, Javier Fernandez, CEO of Vitro S.A, states: “Thanks to the infrastructure of our baseline laboratory in Granada, we are currently validating innovative diagnostic tests for SARSCoV-2 using several technologies, including not only the PCR technologies, but also flow cytometry and other alternative technologies for the detection of both the RNA of the virus and the antibodies developed against the virus, which makes Vitro's capacity to develop and supply different diagnostic tests and technologies for Covid-19 unique within our National Health System”. These new diagnostic tests will be available soon and will allow Spain’s hospital network to have the most cutting-edge diagnostic tools against SARS-CoV-2 currently available.

More Less

About us

Company portrait

We are a Spanish corporation specialized on development, manufacturing and distribution of instruments, software and in vitro diagnostic (IVD) reagents by applying non-invasive techniques, typically used in immunohistochemistry and molecular biology. We commercialize CE-marked IVD multiplex tests for HPV, sepsis diagnosis, AMR, ETS, respiratory viruses and Zoonosis. Additionally, we have extensive experience in PCR-multiplex technology by reverse flow hybridization.

We are determined to technological innovation and personalized treatments, offering the best solutions for IVD diagnosis in different areas. Our main goal is definitely to improve the health status for every patient and in order to achieve this, we are willing to work under the highest quality standards, looking for the excellence of our products and services.

More importantly, we have a highly committed and qualified team to offer the best service and most efficient and accurate diagnostic solutions, adapted to each client’s requirements.

Company data

Sales volume 10-49 Mio US $
Export content max. 50%
Number of employees 100-499
Foundation 1989
Area of business Diagnostic tests

Company information as a PDF file